<DOC>
	<DOCNO>NCT01661166</DOCNO>
	<brief_summary>The investigator assess incidence Overactive Bladder/Detrusor Overactivity ( OAB/DO ) post-operatively patient post robotic assisted radical prostatectomy ( RARP ) investigate whether fesoterodine alter incidence OAB/DO patient . Additionally , correlation OAB symptom urodynamic DO analyze .</brief_summary>
	<brief_title>A Study Effects Fesoterodine Men High Risk Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Men age 30 90 year old prostate adenocarcinoma already make treatment selection RARP , men AUA symptom score great 7 include . All subject must able read comprehend fully inform consent . Men prostate neoplasm adenocarcinoma Subjects receiving treatment prostate cancer exclude . Any subject preexisting bladder disease exclude . Subjects acute urinary retention and/or decease gastointestinal motility . Subjects glaucoma . Subjects hepatic renal impairment . Subjects take CYP3A4 Inhibitors ( e.g.ketoconazole , intraconazole , clarithromycin ) . Subjects myasthenia gravis Subjects unwilling unable complete subject questionnaires Subjects , opinion investigator , would noncompliant majority visit schedule study procedure .</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Male adult subject</keyword>
	<keyword>age 30-90 year</keyword>
	<keyword>RARP</keyword>
	<keyword>AUA symptom score great 7 include</keyword>
</DOC>